3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid has been researched along with haloperidol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlsson, A; Carlsson, ML; Martin, P; Nilsson, M; Sorensen, SM; Waters, N; Waters, S | 1 |
| Lanis, A; Schmidt, WJ | 1 |
2 other study(ies) available for 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid and haloperidol
| Article | Year |
|---|---|
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Fluorobenzenes; Glutamic Acid; Haloperidol; Hyperkinesis; Male; Mice; Mice, Inbred Strains; Motor Activity; N-Methylaspartate; Piperazines; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin Antagonists | 1999 |
NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent.
Topics: Animals; Conditioning, Classical; Drug Interactions; Excitatory Amino Acid Antagonists; Haloperidol; Male; Phenols; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate | 2001 |